Urogen Pharma (NASDAQ:URGN) Stock Rating Lowered by Wall Street Zen

by · The Markets Daily

Urogen Pharma (NASDAQ:URGN – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other analysts also recently commented on the company. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a research report on Friday, October 3rd. HC Wainwright cut their price target on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Piper Sandler started coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Read Our Latest Analysis on URGN

Urogen Pharma Trading Up 0.1%

Shares of Urogen Pharma stock opened at $16.95 on Friday. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.71. The stock has a market cap of $784.11 million, a PE ratio of -5.11 and a beta of 1.00. The company has a 50-day moving average of $18.53 and a two-hundred day moving average of $14.09.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million for the quarter, compared to analysts’ expectations of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. On average, sell-side analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,203 shares of the company’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the transaction, the chief financial officer directly owned 2,280 shares in the company, valued at approximately $38,418. This represents a 49.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. This represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,265 shares of company stock valued at $502,236. 4.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of URGN. Bender Robert & Associates purchased a new position in shares of Urogen Pharma during the 2nd quarter worth $475,000. Nuveen LLC acquired a new position in Urogen Pharma in the first quarter valued at $1,028,000. Rhumbline Advisers lifted its position in Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company’s stock worth $591,000 after buying an additional 2,196 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma in the 1st quarter worth about $194,000. Finally, Parkman Healthcare Partners LLC grew its holdings in Urogen Pharma by 6.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company’s stock valued at $4,348,000 after buying an additional 23,292 shares during the period. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Further Reading